.
.
.
biohaven: "rimegepant pivotal phase 3 trial results -- conference call.".
researchers have developed a new artificial intelligence-based software which may identify and measure the severity of common causes of strokes and.
``much of this delay in implementation can be attributed to the lack of coordination and cooperation between the city and county.''.
.